CBD for Pain Reduction and Opioid Use After Ankle and Tibia Fracture ORIF

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of administering CBD to control post-operative pain in patients undergoing ankle fracture open reduction and internal fixation, tibial plafond (pilon) open reduction and internal fixation, tibial shaft repair (open reduction internal fixation or intramedullary nail fixation), or tibial plateau open reduction and internal fixation. Secondly, the purpose is to evaluate the effectiveness of CBD in comparison with opioid therapy for post-operative pain.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NYU Langone Health

Criteria

Inclusion Criteria:

• Patients undergoing an ankle fracture open reduction and internal fixation (medial malleolus, lateral malleolus, posterior malleolus, and/or syndesmosis repair), tibial plafond (pilon) open reduction and internal fixation, tibial shaft repair (open reduction internal fixation and intramedullary nail fixation), or tibial plateau open reduction and internal fixation

• Patients ages 18-75, inclusive

• Female patients must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly

• Male patients must be using an effective form of contraception

Exclusion Criteria:

• Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)

• Younger than 18 years of age

• Older than 75 years of age

• Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners

• History of cannabis abuse or dependence

• History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values

• History of stroke or acute coronary syndromes within 3 months before surgery

• Abnormal coagulation profile

• Renal failure (serum creatinine > 250 μmol/L [2.83 mg/dL]) or liver cirrhosis

• Patients that have been on pre-operative opioid management for any reason

• Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder

• Patients diagnosed with major depression, psychosis, or substance abuse disorder

• Patients with current or a history of suicidal ideation

• Breastfeeding females

• Patients with clinically significant illness, including cardiovascular disorders

• Clinically significant lab abnormalities

• Abnormal LFTs

• Patients with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures

• Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).

• Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 concomitantly

• Patients taking strong CYP3A4 and CYP2C19 inducers concomitantly